Phaarmasia
109.00
-3.95(-3.50%)
Market Cap₹74.40 Cr
PE Ratio4.35
IndustryHealthcare
Company Performance:
1D-3.50%
1M+37.97%
6M+226.05%
1Y+269.49%
5Y+256.79%
View Company Insightsright
More news about Phaarmasia
13Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Up 26.6% QoQ, Net Profit Rebounds
Phaarmasia Limited announced Q1 FY2026 results with revenue from operations at Rs 687.36 lakhs, up 26.6% QoQ. The company reported a net profit of Rs 27.02 lakhs, compared to a loss in the previous quarter. Total income reached Rs 718.88 lakhs, with total expenses at Rs 687.58 lakhs. EPS for the quarter was Rs 0.40. The company maintained its paid-up equity share capital at Rs 682.70 lakhs and reported zero outstanding loans or debt securities.
 no imag found
11Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Declines 17.1% YoY, Shows Sequential Improvement
Phaarmasia Limited's Q1 FY2026 results show a 17.1% year-over-year revenue decline to Rs. 687.36 lakhs, but a 26.6% sequential increase from Q4 FY2025. Net profit marginally decreased by 2.2% YoY to Rs. 27.02 lakhs. The company returned to profitability after a loss in the previous quarter. Total expenses decreased by 16.1% YoY, helping to mitigate the impact of lower revenue. EPS remained stable at Rs. 0.40.
 no imag found
Phaarmasia
109.00
-3.95
(-3.50%)
1 Year Returns:+269.49%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)